特一药业前三季度净利增长985% 营销组织架构完成全面升级

Core Insights - The company reported significant growth in revenue and net profit for the first three quarters of 2025, with revenue reaching 692 million yuan, a year-on-year increase of 51.86%, and net profit at 65.22 million yuan, up 985.18% [1] - The growth is primarily attributed to a notable increase in sales of traditional Chinese medicine products [1] Financial Performance - In Q3 2025, the company achieved revenue of 201 million yuan, reflecting a year-on-year growth of 41.49%, while net profit for the quarter was 27.21 million yuan, an increase of 719.47% [1] - The company's core product, "Te Yi" cough tablets, sold 331 million pieces in the first half of 2025, recovering to 61.29% of the sales volume compared to the same period in 2023 [2] Marketing and Organizational Changes - The company has completed a comprehensive upgrade of its marketing organizational structure, creating new departments such as self-operated sales, online marketing, third-party sales, brand marketing, and market supervision [2] - The restructuring has led to an increase of over 100 frontline sales personnel, with plans to continue recruiting based on market development needs [2] - The company aims to enhance the market development of potential traditional Chinese medicine products and strengthen its multi-product tier strategy [2]